Elevation nails down $30M for COPD aerosol treatment; Ikaria recalls nitric oxide/inhalation product;

> Elevation Pharmaceuticals has closed $30 million in Series B financing to fund further development of its new aerosol therapy to treat chronic obstructive pulmonary disease, for use in a nebulizer. Release

> The FDA has granted orphan drug designation to Dutch company Amsterdam Molecular Therapeutics for its gene therapy program to treat hemophilia B; in early testing, it appears to reduce the need for protein replacement treatment. Release

> Addenbrooke's Hospital in Cambridge, U.K. has recruited 1,000 diabetic patients to a clinical trial comparing the effectiveness of pumps that deliver insulin directly into the body with the effectiveness of daily multiple injections, the BBC reports. Video

> Ikaria has issued a class I FDA recall notice for its Inomax DS nitric oxide/inhalation product, which treats hypoxic respiratory failure relating to hypertension in infants; health professionals have been notified and the problem corrected, the company said.  Release

> French regulators have approved United Therapeutics' use of Remodulin (treprostinil) by continuous subcutaneous infusion to treat pulmonary arterial hypertension. Story

> Arrowhead Research ($ARWR) has gained FDA clearance to begin a Phase I clinical trial of its obesity drug AdipotideTM, a nanomedicine treatment that targets and kills blood vessels supplying white fat tissue. Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.